Endovastec(SH:688016) Sou Hu Cai Jing·2025-07-30 12:04Core Viewpoint - The company, Xinmai Medical, is experiencing a decline in stock price and financial performance, with a current PE ratio significantly lower than the industry average, indicating potential undervaluation in the context of the medical device sector [1][2]. Company Overview - Xinmai Medical specializes in the research, production, and sales of interventional medical devices for aortic and peripheral blood vessels, with key products including thoracic and abdominal aortic stent graft systems, intraoperative stents, and balloon catheters [2]. - The company has received several accolades, including the Shanghai Government Quality Gold Award and recognition as one of the top 30 companies in the Sci-Tech Innovation Board [2]. Financial Performance - For Q1 2025, Xinmai Medical reported revenue of 332 million yuan, a year-on-year decrease of 7.23%, and a net profit of 130 million yuan, down 29.66% from the previous year, with a gross margin of 69.61% [2]. - The current stock price is 111.61 yuan, with a PE ratio of 30.75, compared to the industry average of 55.15 and a median of 37.48 [1][3]. Shareholder Information - As of March 31, 2025, Xinmai Medical has 18,176 shareholders, an increase of 523 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1].